Radiation therapy oncology group clinical trials for carcinoma of the cervix

International Journal of Gynecological Cancer

Volumn 9, Issue 6, 1999, Pages 439-447

  Grigsby, P W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervix; Clinical trials; RTOG

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; MITOMYCIN C;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HYPOXIC CELL; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

EID: 0033376366     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.99036.x     Document Type: Review

References (12)

1. Brady LW, Plenk HP, Hanley JA, Glassburn JR, Kraer S, Parker RG. Hyperbaric oxygen therapy for carcinoma of the cervix - Stages IIB IIIA IIIB and IVA results of a randomized study by the Radiation Therapy Oncology Group, Int J Radiat Oncol Biol Phys 1981;7:991-8.
2. Marcial VA, Amato DA, Marks RD et al. Split-course versus continuous pelvis irradiation in carcinoma of the uterine cervix: a prospective randomized clinical trial of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1983;9:431-6.
3. Maor MH, Gillespie BW, Peters LJ et al. Neutron therapy in cervical cancer: results of a phase III RTOG study. Int J Radiat Oncol Biol Phys 1988;14:885-91.
4. Meoz RT, Spanos WJ, Doss L, Johnson R, Wasserman TH. Misonidazole combined with large-fraction pelvic irradiation in the treatment of patients with advanced pelvic malignancies. Preliminary report of an ongoing RTOG phase I-II study. Am J Clin Oncol 1983;6:417-22.
5. Leibel S, Bauer M, Wasserman T et al. Radiotherapy with or without misonidazole for patients with stage IIIB or stage IVA squamous cell carcinoma of the uterine cervix: Preliminary report of a Radiation Therapy Oncology Group randomized trial, Int J Radiat Oncol Biol Phys 1987;13:541-9.
6. Grigsby PW, Winter K, Wasserman TH et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 80-05. Int J Radiat Oncol Biol Phys 1999;44:513-7.
7. Coleman CN, Noll L, Riese N et al. Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study, Int J Radiat Oncol Biol Phys 1992;22:577-80.
8. Rotman M, Pajak T, Choi K et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinoma: ten-year treatment results of RTOG 79-20. JAMA 1995;274:387-93.
9. John M, Flam M, Caplan R et al. Final results of a phase II chemoradiation protocol for locally advanced cervical cancer: RTOG 85-15. Gynecol Oncol 1996;61:221-6.
10. Komaki R, Pajak TF, Marcial VA et al. Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the Radiation Therapy Oncology Group 88-05. Cancer 1994;73:2619-25.
11. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with con-current chemotherapy compared with pelvic and para aortic radiation for high-risk cervical cancer. N Eng J Med 1999;340:1137-43.
12. Grigsby PW, Lu JD, Mutch DG, Kim RY, Eifel PJ. Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes. Phase II study of the Radiation Therapy Oncology Group 92-10. Int J Radiat Oncol Biol Phys 1997;39 (Suppl. 2):208.